Skyline Ventures
79
28M
42
2.93
13
0.47
31
- Stages of investment
- Areas of investment
Summary
In 1997 was created Skyline Ventures, which is appeared as VC. The main department of described VC is located in the Palo Alto. The company was established in North America in United States.
Opposing the other organizations, this Skyline Ventures works on 11 percentage points more the average amount of lead investments. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 deals per year. When the investment is from Skyline Ventures the average startup value is 10-50 millions dollars. The top activity for fund was in 2006. The increased amount of exits for fund were in 2014. Considering the real fund results, this VC is 1 percentage points less often commits exit comparing to other organizations.
Among the various public portfolio startups of the fund, we may underline NovaSys, Calibra Medical, Satiety Besides, a startup needs to be aged 4-5 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has exact preference in some founders of portfolio startups. Among the most successful fund investment fields, there are Medical Device, Hospital.
The current fund was established by Eric M Gordon, John Freund. We also calculated 3 valuable employees in our database.
The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Skyline Ventures, startups are often financed by TVM Capital, SV Health Investors, Intersouth Partners. The meaningful sponsors for the fund in investment in the same round are TVM Capital, Intersouth Partners, InterWest Partners. In the next rounds fund is usually obtained by TVM Capital, Intersouth Partners, Montreux Equity Partners.
Investments analytics
Analytics
- Total investments
- 79
- Lead investments
- 13
- Exits
- 31
- Rounds per year
- 2.93
- Follow on index
- 0.47
- Investments by industry
- Biotechnology (61)
- Health Care (47)
- Medical (44)
- Pharmaceutical (22)
- Medical Device (11) Show 22 more
- Investments by region
-
- United States (77)
- China (2)
- Peak activity year
- 2006
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 19
- Avg. valuation at time of investment
- 127M
- Group Appearance index
- 0.96
- Avg. company exit year
- 11
- Avg. multiplicator
- 2.07
- Strategy success index
- 0.60
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Collegium Pharmaceutical | 15 Feb 2012 | Biotechnology, Medical, Life Science, Therapeutics | Early Stage Venture | 22M | United States, Massachusetts |
Tetraphase Pharmaceuticals | 01 Jun 2010 | Biotechnology, Health Care, Biopharma | Late Stage Venture | 45M | United States, Massachusetts |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.